Alzhemed: A potential treatment for Alzheimer's disease

Current Alzheimer Research

Volumn 4, Issue 4, 2007, Pages 473-478

  Aisen, Paul S ^a,e   Gauthier, Serge ^b   Vellas, Bruno ^c   Briand, Richard ^d   Saumier, Daniel ^d   Laurin, Julie ^d   Garceau, Denis ^d  

^a GEORGETOWN UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c Alzheimer Clinical and Research Center   (France)

^d Neurochem Inc   (Canada)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 PROPANEDISULFONIC ACID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE INHIBITOR; FLURBIPROFEN; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; NEUROTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PLACEBO; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; AMYLOIDOSIS; BLOOD BRAIN BARRIER; BRAIN; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING SCALE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DRUG BINDING; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MINI MENTAL STATE EXAMINATION; NAUSEA; NONHUMAN; PLASMA; PRIORITY JOURNAL; RATING SCALE; VOMITING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS;

EID: 34548689646     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720507781788882     Document Type: Conference Paper

References (32)

1. Giacobini E, editor. Cholinesterases and Cholinesterase Inhibitors. London: Martin Dunitz Ltd, (2000).
2. Creeley C, Wozniak DF, Labruyere J, Taylor GT, Olney JW. Low Doses of Memantine Disrupt Memory in Adult Rats. J Neurosci 26:3923-32 (2006).
3. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-41 (2003).
4. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama 291:317-24 (2004).
5. Cummings JL. Alzheimer's disease. N Engl J Med 351:56-67 (2004).
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-6 (2002).
7. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24:10191-200 (2004).
8. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, et al. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem 281:1599-604 (2006).
9. Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs 19:989-96 (2005).
10. Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta- secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10:1317-24 (2001).
11. Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4:231-2 (2001).
12. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-6 (2001).
13. Molecule of the month. MPC-7869 (Flurizan). Drug News Perspect 18:141 (2005).
14. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553-62 (2005).
15. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 3:3(2001).
16. Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23:29-33 (2003).
17. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26:207-14 (2003).
18. Raman B, Ban T, Yamaguchi K, Sakai M, Kawai T, Naiki H, et al. Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide. J Biol Chem 280:16157-62 (2005).
19. Klunk WE, Debnath ML, Koros AC, Pettegrew JW. Chrysamine-G, a lipophilic analogue of Congo red, inhibits Abeta-induced toxicity in PC12 cells. Life Sci 63:1807-14 (1998).
20. Gervais F, Paquette J, Morissette C, Krzwkowski P, Yu M, Azzi M, et al. Targeting soluble Aβ peptide with 3APS for the treatment of brain amyloidosis. Neurobiol Aging in press (2006).
21. Gervais F, Chalifour R, Garceau D, Kong X, Laurin J, McLaughlin R, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 8 Suppl 1:28-35 (2001).
22. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, et al. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281:4292-9 (2006).
23. Dodel RC, Du Y, Depboylu C, Hampel H, Frolich L, Haag A, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 75:1472-4 (2004).
24. Folstein M, Folstein S, Mchugh P. The Mini-Mental State Examination. J Psychiatric Res 1975;12:189-98.
25. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psych 141:1356-64 (1984).
26. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43:2412-4 (1993).
27. Barten DM, Guss VL, Corsa JA, Loo AT, Hansel SB, Zheng M, et al. Dynamics of {beta}-Amyloid Reductions in Brain, Cerebrospinal Fluid and Plasma of {beta}-Amyloid Precursor Protein Transgenic Mice Treated with a {gamma}-Secretase Inhibitor. J Pharmacol Exp Ther 312:635-43 (2004).
28. Best JD, Jay MT, Otu F, Churcher I, Reilly M, Morentin-Gutierrez P, et al. In vivo characterisation of A{beta}(40) changes in brain and CSF using the novel {gamma}-secretase inhibitor MRK-560 (N-[cis-4-[(4-chlorophenyl) sulfonyl]-4- (2,5-difluorophenyl)cyclohexyl]-1,1,1- trifluoromethanesulfonamide) in the rat. J Pharmacol Exp Ther 317:786-90 (2006).
29. Lemere CA, Beierschmitt A, Iglesias M, Spooner ET, Bloom JK, Leverone JF, et al. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am J Pathol 2004;165:283-97.
30. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Amer J Psychiatry 151:390-6 (1994).
31. Cummings J. The neuropsychiatric inventory: Assessing psychopathology in dementia patients. Neurology 48 (Suppl 6):S10-S6 (1997).
32. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 53:471-81 (1999).